Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

by Daniel Y.C. Heng, Ronald M. Bukowski
Published 2011-12-01

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

by Daniel Y.C. Heng, Ronald M. Bukowski
Published 2011-12-01

High-risk bladder cancer: improving outcomes with perioperative chemotherapy

by Daniel Y.C. Heng, Jorge A. Garcia
Published 2011-12-01

High-risk bladder cancer: improving outcomes with perioperative chemotherapy

by Daniel Y.C. Heng, Jorge A. Garcia
Published 2011-12-01

Contemporary treatment of metastatic renal cell carcinoma

by Igor Stukalin, Nimira Alimohamed, Daniel Y.C. Heng
Published 2016-07-01

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

by Jose Manuel Ruiz-Morales, Daniel Y.C. Heng
Published 2016-12-01

Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

by Daniel Y.C. Heng, Christian Kollmannsberger, Kim N. Chi
Published 2010-01-01

Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies

by Steven M Yip, Daniel Y. C. Heng, Patricia A. Tang
Published 2016-03-01

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

by Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Published 2021-04-01

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

by Daniel E. Meyers, Igor Stukalin, Isabelle A. Vallerand, Ryan T. Lewinson, Aleksi Suo, Michelle Dean, Scott North, Aliyah Pabani, Tina Cheng, Daniel Y.C. Heng, D. Gwyn Bebb, Don G. Morris
Published 2019-11-01

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

by Domen Ribnikar, Igor Stukalin, Philippe L. Bedard, Robert J. Hamilton, Michael Jewett, Padraig Warde, Peter Chung, Lynn Anson-Cartwright, Arnoud J. Templeton, Eitan Amir, Aaron R. Hansen, Daniel Y. C. Heng, Jeremy Lewin
Published 2021-12-01

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Published 2018-10-01

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers
Published 2019-03-01

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

by Xiao Wei, Marina D Kaymakcalan, Daniel Y C Heng, Wanling Xie, Sarah Abou Alaiwi, Amin H Nassar, Shaan Dudani, Dylan Martini, Ziad Bakouny, John A Steinharter, Pier Vitale Nuzzo, Ronan Flippot, Nieves Martinez-Chanza, Bradley A McGregor, Mehmet A Bilen, Lauren C Harshman
Published 2020-06-01

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Rena...

by Chun Loo Gan, Shaan Dudani, J. Connor Wells, Frede Donskov, Sumanta K. Pal, Nazli Dizman, Nityam Rathi, Benoit Beuselinck, Flora Yan, Aly‐Khan A. Lalani, Aaron Hansen, Bernadett Szabados, Guillermo deVelasco, Ben Tran, Jae Lyun Lee, Ulka N. Vaishampayan, Georg A. Bjarnason, Mathushan Subasri, Toni K. Choueiri, Daniel Y. C. Heng
Published 2021-02-01

Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the glo...

by Ben Tran, Jose M. Ruiz‐Morales, Enrique Gonzalez‐Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Christian Fankhauser, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Fléchon, Edmond Michael Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia del Muro, Anis A. Hamid, Margaret Ottaviano, Giovannella Palmieri, Robert Kitson, Alison Reid, Daniel Y. C. Heng, Philippe L. Bedard
Published 2020-01-01

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma

by Ziad Bakouny, David A. Braun, Sachet A. Shukla, Wenting Pan, Xin Gao, Yue Hou, Abdallah Flaifel, Stephen Tang, Alice Bosma-Moody, Meng Xiao He, Natalie Vokes, Jackson Nyman, Wanling Xie, Amin H. Nassar, Sarah Abou Alaiwi, Ronan Flippot, Gabrielle Bouchard, John A. Steinharter, Pier Vitale Nuzzo, Miriam Ficial, Miriam Sant’Angelo, Juliet Forman, Jacob E. Berchuck, Shaan Dudani, Kevin Bi, Jihye Park, Sabrina Camp, Maura Sticco-Ivins, Laure Hirsch, Sylvan C. Baca, Megan Wind-Rotolo, Petra Ross-Macdonald, Maxine Sun, Gwo-Shu Mary Lee, Steven L. Chang, Xiao X. Wei, Bradley A. McGregor, Lauren C. Harshman, Giannicola Genovese, Leigh Ellis, Mark Pomerantz, Michelle S. Hirsch, Matthew L. Freedman, Michael B. Atkins, Catherine J. Wu, Thai H. Ho, W. Marston Linehan, David F. McDermott, Daniel Y. C. Heng, Srinivas R. Viswanathan, Sabina Signoretti, Eliezer M. Van Allen, Toni K. Choueiri
Published 2021-02-01